Multiple COVID-19 Vaccines Show High Efficacy

Strategic Insights -

The development of COVID-19 vaccines has led to promising results, with multiple vaccines demonstrating high efficacy against the virus. The vaccines, developed by various companies and institutions, have taken different approaches to creating immunity against COVID-19. COVID-19 vaccines have undergone extensive testing, with some showing remarkable results.

Key Takeaways:

  • Pfizer and BioNTech's vaccine, which uses messenger RNA (mRNA) to instruct muscle cells to make a piece of the virus's spike protein, has shown 95% efficacy in preventing symptomatic infections.
  • Moderna's vaccine, also based on mRNA, has demonstrated 94% efficacy in preventing symptomatic infections and 85% efficacy in preventing all infections, including those that do not cause symptoms.
  • Johnson & Johnson's vaccine, a recombinant vector vaccine, has shown 66% efficacy in preventing moderate and severe disease and 85% efficacy in preventing severe disease.
  • AstraZeneca's vaccine, a vector vaccine, has demonstrated 67% efficacy in preventing symptomatic infections, with studies indicating a single dose of vaccine can prevent 76% of symptomatic infections for up to 90 days.
  • Novavax's vaccine, a protein subunit vaccine, has shown 89% efficacy in a Phase 3 trial and 95.6% efficacy against the original novel coronavirus.
  • Sanofi and GlaxoSmithKline's vaccine, also a protein subunit vaccine, has elicited an immune response in younger adults comparable to patients who recovered from COVID-19.
  • Sinovac's vaccine, an inactivated virus vaccine, has been shown to be effective against the B.1.351 variant, and Sinopharm's vaccine has also demonstrated efficacy against the same variant.
  • Sputnik V, a two-dose adenoviral vector vaccine, has shown 91.6% efficacy and 100% efficacy for preventing severe illness.

Statistics:

  • Pfizer's vaccine must be kept at ultracold temperatures of about minus 100 degrees Fahrenheit (minus 75 degrees Celsius).
  • Moderna's vaccine can be shipped at minus 20 degrees C (minus 4 degrees F) and can be kept stable for 30 days at 2 degrees to 8 degrees C (36 to 46F).
  • Johnson & Johnson's vaccine can be stored at normal refrigerator temperatures.
  • AstraZeneca's vaccine can be kept stable for six months at standard refrigerator temperatures.
  • Novavax's vaccine has been shown to be 60% effective against the B.1.351 variant in a Phase 2b study in South Africa.
  • Sputnik V has demonstrated 100% efficacy for preventing severe illness.

Sources:

  • Pfizer/BioNTech: Pfizer and BioNTech's COVID-19 vaccine, BioNTech, and US Centers for Disease Control and Prevention (CDC).
  • Moderna: Moderna's COVID-19 vaccine, Moderna, and US Centers for Disease Control and Prevention (CDC).
  • Johnson & Johnson: Johnson & Johnson's COVID-19 vaccine, Janssen Pharmaceuticals, and US Centers for Disease Control and Prevention (CDC).
  • AstraZeneca: AstraZeneca's COVID-19 vaccine, AstraZeneca, and Lancet preprint.
  • Novavax: Novavax's COVID-19 vaccine, Novavax.
  • Sanofi and GlaxoSmithKline: Sanofi and GlaxoSmithKline's COVID-19 vaccine, Sanofi, and GlaxoSmithKline.
  • Sinovac: Sinovac's COVID-19 vaccine, Sinovac, and China's Center for Disease Control.
  • Sputnik V: Sputnik V's COVID-19 vaccine, Sputnik V, and Lancet medical journal.